Remove Manufacturing Remove Medical Remove Provider Remove Supply Chain
article thumbnail

9 Technologies That Will Shape The Future Of Dentistry

The Medical Futurist

Just like in the case of other medical specialties , disruptive innovations will have a huge impact on how dentistry will be practiced and how patients will take care of themselves in the future. Can you imagine that you might get your 3D-printed prosthesis in an hour instead of 4-5 sessions at the dentist?

Patients 126
article thumbnail

The Rising Tide of Medical Waste: One Model for Improvement

My Green Doctor

Author: Ishani Majmudar Medical waste is rising tremendously each year, and its implications are not slight. Medical waste is a broad term used to describe any waste products generated at healthcare facilities and includes everything ranging from the disposal of small needles to the energy consumption of radiologic scans. 3 “Each U.S.

Medical 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Wholesaling Prohibition (Potentially) Demystified? FDA’s Take on Supply Chains for Section 503B Outsourcing Facilities

FDA Law

Under section 503B, drugs compounded by an FDA-registered outsourcing facility under the supervision of a licensed pharmacist can qualify for exemptions from FDA approval, labeling with adequate directions for use, and certain drug supply chain security requirements, subject to specific conditions. See 21 U.S.C. Section II at 2.

article thumbnail

Why, Who, When, Where and More: New Draft Guidance on Notifying FDA about Discontinuance or Interruption in Manufacturing

FDA Law

By Véronique Li, Senior Medical Device Regulation Expert & Deborah L. Livornese — On February 6, 2024, FDA issued a draft guidance titled Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act.

article thumbnail

FDA Takes Another Small Step to Increase Naloxone Access

FDA Law

Most states have some form of naloxone standing order that allows a healthcare provider to write a prescription that covers a large group of people rather than just an individual patient. Because naloxone is a prescription drug, its distribution is subject to the requirements of the Drug Supply Chain Security Act (DSCSA).

article thumbnail

The Wait is — Almost — Over: The Long-Anticipated Proposed Rule for Drug Wholesale Distributors and 3PLs is Out: Comments Due in 120 Days

FDA Law

Richardson — FDA has released its Proposed Rule of National Standards for Third-Party Logistics Providers (“3PLs”) and Prescription Drug Wholesale Distributors (“WDDs”). The Rule, if enacted in its current form, will have sweeping implications throughout the supply chain, but particularly for WDDs and 3PLs. By Karla L.

article thumbnail

What is Special about September 24, 2023 for the UDI System?

FDA Law

Baumhardt, Senior Medical Device Regulation Expert — The Unique Device Identification (UDI) System final rule requires all medical devices to bear a unique numeric or alphanumeric code in easily readable plain-text and machine-readable form. Finally, as a general matter, every firm needs to make sure its supply chain stakeholders (e.g.,